Extended use of AZ’ Brilinta cuts CV death risk 29%

24th August 2017 Uncategorised 0

Long-term use of AstraZeneca’s Brilinta in patients with a history of heart attack reduces the risk of cardiovascular death by 29 percent, a new sub analysis of data from the Phase III PEGASUS-TIMI 54 trial has found.

More: Extended use of AZ’ Brilinta cuts CV death risk 29%
Source: News